US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Agendia, Inc.

News headline image
Largest Real-World Evidence Study in Early-Stage Breast Cancer; FLEX Surpasses 25,000 Patients
From Agendia, Inc.
Via Business Wire
News headline image
Genomic Profiling With MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Genomic Profiling with MammaPrint® + BluePrint® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Announces Publication in JNCI Cancer Spectrum Demonstrating that MammaPrint® Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer Using Real-World Evidence from the FLEX Study
From Agendia, Inc.
Via Business Wire
News headline image
Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO® Annual Meeting
From Agendia, Inc.
Via Business Wire
News headline image
Agendia to Unveil Novel Data on Genomic Risk and Treatment Disparities in Early-Stage Breast Cancer at 2025 ASCO® Annual Meeting
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Spotlights New Data on Genomic Testing at 26th American Society of Breast Surgeons Annual Meeting
From Agendia, Inc.
Via Business Wire
News headline image
Agendia, Inc. Provides Review of Successful 2024
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Demonstrates MammaPrint® Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Announces Publication Validating MammaPrint® Utility in Prediction of Extended Endocrine Therapy Benefit
From Agendia, Inc.
Via Business Wire
News headline image
Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Co-Founder Prof. Dr. Laura van 't Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics
From Agendia, Inc.
Via Business Wire
News headline image
Agendia's FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Achieves CE-IVDR Certification for its MammaPrint® and BluePrint® Breast Cancer Assays
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Announces Publication of Utility of MammaPrint® in Prediction of Extended Endocrine Therapy in Journal of Clinical Oncology
From Agendia, Inc.
Via Business Wire
News headline image
Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO
From Agendia, Inc.
Via Business Wire
News headline image
German Gynecological Oncology Group (AGO) Recognizes BluePrint® in Breast Cancer Guidelines
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Appoints Ronald Andrews and David Schreiber to Board of Directors
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Studies Reveal the Influence of Race on a Tumor’s Biology, Reinforcing its Commitment to Advancing Research of Racial Disparities in Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Research Shows Highest Risk MammaPrint® Category Predicts Strongest Chemosensitivity in Women with Early-Stage HR+HER2- Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Announces First Patient Enrolled in PROOFS Registry Trial to Determine Optimal Treatment and Ability to Forgo Chemotherapy for Premenopausal Women with Early HR+ Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Updated NCCN® Guidelines Recognize MammaPrint® UltraLow Risk Result, Highlighting its Clinical Utility for Women with Early-Stage Breast Cancer Who Can Safely Forgo Toxic Treatments with Excellent Survival Rates
From Agendia, Inc.
Via Business Wire
News headline image
Level One Evidence Proves Premenopausal Patients within the Ultra-Low Subset of Agendia’s MammaPrint Low Risk Result Can Safely Forgo Chemotherapy
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Announces First Patient Enrolled in Prospective LESS Clinical Study, Sponsored by Unicancer, to De-escalate Endocrine Therapy in Women with Early Breast Cancer
From Agendia, Inc.
Via Business Wire
News headline image
Agendia Presents Data from the FLEX Real World Evidence Trial in Seven Posters at ASCO 2022, Showcasing the Power of Its 30,000-Patient Breast Cancer Genome Project
From Agendia, Inc.
Via Business Wire